Lupin is currently trading at Rs 1440.05, up by 9.15 points or 0.64% from its previous closing of Rs. 1430.90 on the BSE.
The scrip opened at Rs 1435.00 and has touched a high and low of Rs 1446.00 and Rs 1418.05 respectively. So far 26593 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 1500.00 on 24-Nov-2014 and a 52 week low of Rs 855.00 on 30-Jan-2014.
Last one week high and low of the scrip stood at Rs 1495.00 and Rs 1420.65 respectively. The current market cap of the company is Rs. 64799.52 crore.
The promoters holding in the company stood at 46.69%, while Institutions and Non-Institutions held 42.71% and 10.60% respectively.
Pharma Major Lupin’s US subsidiary, Lupin Pharmaceuticals Inc has launched the authorized generic for G.D. Searle LLC’s (a subsidiary of Pfizer Inc)’ Celebrex Capsules (Celebrex) , which are available in 50 mg, 100 mg, 200 mg and 400 mg strengths. Lupin had earlier signed a licensing agreement with Pfizer Inc for Celebrex.
Celebrex Capsules had annual US sales of $ 2.54 billion, according to IMS MAT September, 2014.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1462.50 |
Dr. Reddys Lab | 5784.50 |
Cipla | 1451.25 |
Zydus Lifesciences | 1001.15 |
Lupin | 1587.90 |
View more.. |